| Outcome Measures: |
Primary: The maximum plasma concentration (Cmax) of SP2086, Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086, up to Day 13|The steady-state plasma concentration (Css) of SP2086, Css (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086, up to Day 13|The maximum plasma concentration (Cmax) of SP2086 acid, Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086, up to Day 13|The steady-state plasma concentration (Css) of SP2086 acid, Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086, up to Day 13|The maximum urine concentration (Cmax) of SP2086, Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086, up to Day 13|The steady-state urine concentration (Css) of SP2086, Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086, up to Day 13|The maximum urine concentration (Cmax) of SP2086 acid, Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086, up to Day 13|The steady-state urine concentration (Css) of SP2086 acid, Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086, up to Day 13 | Secondary: The number of volunteers with adverse events as a measure of safety and tolerability, up to Day 13
|
